Fig. 1: The characteristics of SETD2 mutations in TCGA pan-cancer cohort.
From: Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
a The prevalence of SETD2 mutations across tumors. b The subtypes and distributions of SETD2 somatic mutations. X-axis, amino acid; Y-axis, numbers of SETD2 mutations; green box, SET domain (1561–1667); red box, WW domain (2391–2420); blue box, SRI domain (2466–2558); green dot, missense mutation; black dot, truncating mutation; orange dot, inframe mutation. c Location of variants on the 3D protein structure of SETD2. Purple, mutated amino acid. d Tumor mutation burden (TMB) in SETD2 nonmutant cancer and different subtypes of SETD2 mutant cancer. Each gray dot represents one patient, black line represents the median TMB and its interquartile ranges. e The prevalence of SETD2 mutation and median TMB in multiple tumors. Red line, fitted curve; HNC, head and neck cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma. f MSIsensor scores in SETD2 nonmutant cancer and different subtypes of SETD2 mutant cancer. g MSI MANTIS scores in SETD2 nonmutant cancer and different subtypes of SETD2 mutant cancer. h The mutant frequencies of MSH2, MSH6, MLH1, and PMS2 in SETD2 mutant and nonmutant cancer. i Overall survival (OS) analysis stratified by SETD2 mutation status in the whole TCGA cohort. j Disease-free survival (DFS) analysis stratified by SETD2 mutation status in TCGA. k Disease-specific survival (DSS) analysis stratified by SETD2 mutation status in TCGA. l Progress-free survival (PFS) analysis stratified by SETD2 mutation status in TCGA. NS, P > 0.05; *P < 0.05; ***P < 0.001.
